Sun BioPharma

    OverviewSuggest Edit

    Sun BioPharma Inc. is a next-generation biopharmaceutical company developing disruptive therapeutics for serious unmet medical needs. The company’s initial programs are aimed at diseases of the pancreas, including pancreatic cancer and pancreatitis. Its lead product candidate is SBP-101, which is in Phase I clinical trial for the treatment of patients with pancreatic cancer.
    TypePublic
    Founded2011
    HQPonte Vedra Beach, US
    Websitesunbiopharma.com

    Latest Updates

    Employees (est.) (Feb 2019)5(-44%)

    Key People/Management at Sun BioPharma

    Michael T. Cullen

    Michael T. Cullen

    Executive Chairman
    Thomas X. Neenan

    Thomas X. Neenan

    Co-Founder and Chief Scientific Officer
    Tammy Groene

    Tammy Groene

    Vice President of Operations
    Michael Walker

    Michael Walker

    Pancreatic Research Consultant
    Show more

    Sun BioPharma Office Locations

    Sun BioPharma has an office in Ponte Vedra Beach
    Ponte Vedra Beach, US (HQ)
    Ponte Vedra Beach, FL 32082, USA
    Show all (1)

    Sun BioPharma Financials and Metrics

    Sun BioPharma Revenue

    USD

    Net income (FY, 2018)

    (5.9m)

    EBIT (FY, 2018)

    (3.9m)

    Cash (31-Dec-2018)

    1.4m
    Annual
    USDFY, 2013FY, 2015FY, 2016FY, 2017FY, 2018

    Cost of goods sold

    250.5k

    General and administrative expense

    2.6m2.7m3.4m2.1m

    R&D expense

    279.8k2.9m2.5m2.6m1.8m

    Operating expense total

    609.7k5.4m5.2m6.0m3.9m
    Quarterly
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2018Q2, 2018

    Cost of goods sold

    157.5k161.5k24.0k16.7k22.6k

    General and administrative expense

    429.0k481.0k419.0k499.0k658.0k1.3m

    R&D expense

    341.0k494.0k530.0k636.0k580.0k1.0m

    Operating expense total

    70.1k770.0k975.0k949.0k1.1m1.2m2.3m
    Annual
    USDFY, 2013FY, 2015FY, 2016FY, 2017FY, 2018

    Cash

    58.8k925.0k438.0k152.0k1.4m

    Accounts Receivable

    14.8k

    Current Assets

    432.8k1.7m877.0k767.0k1.8m

    PP&E

    19.2k
    Quarterly
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2018Q2, 2018

    Cash

    103.8k71.1k122.9k131.6k64.8k1.8m383.0k1.9m1.2m1.2m905.0k

    Accounts Receivable

    19.7k21.3k15.7k17.4k12.0k

    Current Assets

    395.3k388.7k367.0k279.2k185.0k2.0m1.5m2.1m1.6m1.8m1.5m

    PP&E

    13.2k16.5k14.2k15.2k8.7k
    Annual
    USDFY, 2013FY, 2015FY, 2016FY, 2017FY, 2018

    Net Income

    (212.0k)(4.9m)(5.1m)(10.4m)(5.9m)

    Depreciation and Amortization

    8.8k

    Accounts Payable

    (24.1k)681.0k726.0k(319.0k)360.0k

    Cash From Operating Activities

    (3.9m)(2.4m)(3.4m)(2.4m)
    Quarterly
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2018Q2, 2018

    Net Income

    (191.9k)(110.6k)(167.9k)(263.6k)(4.2m)(824.0k)(1.8m)(2.9m)(1.8m)(4.2m)

    Depreciation and Amortization

    6.1k2.7k5.0k7.3k

    Accounts Payable

    (14.2k)8.7k8.6k(629.0)208.0k493.0k500.0k787.0k111.0k(67.0k)

    Cash From Operating Activities

    (3.0m)(542.0k)(631.0k)(1.6m)(588.0k)(1.6m)
    USDY, 2018

    Financial Leverage

    7.1 x
    Show all financial metrics

    Sun BioPharma Online and Social Media Presence

    Embed Graph

    Sun BioPharma News and Updates

    Sun BioPharma, Inc. Provides a Business Update and Files Report for Q2 2019

    MINNEAPOLIS, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (OTCQB: SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of pancreatic diseases, today provides a business update and reports financial results for the quarter ended June 30, 20…

    Sun BioPharma, Inc. Provides a Business Update and Files Report for Q1 2019

    MINNEAPOLIS, May 14, 2019 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (OTCQB:SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of pancreatic diseases, today provides a business update and reports financial results for the quarter ended March 31, 201…

    Sun BioPharma Provides Business Update and Files Annual Report for 2018

    MINNEAPOLIS, March 22, 2019 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (OTCQB: SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of pancreatic diseases, today provides a business update and reports financial results for the year ended December 31, …

    Sun BioPharma Blogs

    SBP to Present Results of New Study at American Pancreatic Association Meeting

    New study entitled “Effect of SBP-101 in a Mouse Model of Cerulein-induced Acute Pancreatitis” will be presented at the American Pancreatic Association meeting in Miami, FL on Nov. 1. View/download press release » View/download poster presentation » The post SBP to Present Results of New Study at Am…

    SBP Announces Leadership Changes

    David B. Kaysen Steps Down as President, CEO and Board Member Effective October 31, 2018 Michael T. Cullen MD, MBA, Executive Chairman, Elected President and CEO by Board of Directors Effective October 31, 2018 View/download press release » The post SBP Announces Leadership Changes appeared first on…

    SBP Provides a Business Update and Files Report for Q2 2018

    First Patients Enrolled in Front-Line Combination Study of SBP-101 with Gemcitabine and nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer Additional Funds Raised during Q2 View/download press release » The post SBP Provides a Business Update and Files Report for Q2 2018 appeared first…

    SBP Presents Poster at PancreasFest in Pittsburgh PA

    Results of Phase 1 Safety Study of SBP-101 for Pancreatic Ductal Adenocarcinoma PancreasFest is an International Conference of Physicians and Scientists Focused on Pancreatic Diseases View/download press release » View/download poster presentation » View/download PDF presentation The post SBP Presen…

    SBP Doses First Patients in 2nd Clinical Study of SBP-101

    SUN BIOPHARMA, INC. DOSES FIRST PATIENTS IN SECOND CLINICAL STUDY OF SBP-101 FOR PANCREATIC DUCTAL ADENOCARCINOMA After Successful Completion of the Phase 1 Dose Escalation/Safety Study of SBP-101, New Combination Study Opens for Previously Untreated Metastatic Pancreatic Cancer Patients SBP-101 is …

    Sun BioPharma Frequently Asked Questions

    • When was Sun BioPharma founded?

      Sun BioPharma was founded in 2011.

    • Who are Sun BioPharma key executives?

      Sun BioPharma's key executives are Michael T. Cullen, Thomas X. Neenan and Tammy Groene.

    • How many employees does Sun BioPharma have?

      Sun BioPharma has 5 employees.

    • Who are Sun BioPharma competitors?

      Competitors of Sun BioPharma include Biogen, Inovio Pharmaceuticals and MyoKardia.

    • Where is Sun BioPharma headquarters?

      Sun BioPharma headquarters is located at Ponte Vedra Beach, FL 32082, USA, Ponte Vedra Beach.

    • Where are Sun BioPharma offices?

      Sun BioPharma has an office in Ponte Vedra Beach.

    • How many offices does Sun BioPharma have?

      Sun BioPharma has 1 office.